Study on Cost-Effectiveness of Personality disorder TREatment

ISRCTN	ISRCTN73817429
DOI	https://doi.org/10.1186/ISRCTN73817429
Protocol serial number	N/A
Sponsor	Viersprong Institute for Studies on Personality Disorders (VISPD) (The Netherlands)
Funder	Psychotherapeutic Center De Viersprong (The Netherlands)

Submission date: 28/12/2006
Registration date: 28/12/2006
Last edited: 16/01/2007

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Mental and Behavioural Disorders

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Helene Andrea
Scientific

Viersprong Institute for Studies on Personality Disorders (VISPD)
P.O. Box 7
Halsteren
4660 AA
Netherlands

Phone	+31 (0)16 463 2200
Email	helene.andrea@deviersprong.nl

Study information

Primary study design	Interventional
Study design	Non-randomised clinical trial
Secondary study design	Multi-centre
Scientific title
Study acronym	SCEPTRE
Study objectives	1. Effect sizes of the psychotherapeutic treatments vary between 0.5 and 2.0. 2. A lower dosage of psychotherapeutic treatment is mainly related to symptomatic improvement, while a higher dosage is also related to structural and functional improvement. 3. The dosage for an optimal cost-effectiveness is lower than the maximum dosage. 4. When compared to cluster B personality disorders, for cluster C personality disorders a lower dosage is required to reach optimal cost-effectiveness. 5. A lower level of psychological mindedness and/or ability for a positive working alliance with the therapist is related to a lower level of (cost)-effectiveness.
Ethics approval(s)	Approval received from the Research Ethics Committee (REC) of Erasmus Medical Centre, Rotterdam, on the 7th January 2004 (ref: MEC 229.834/2003/122).
Health condition(s) or problem(s) studied	Personality Disorder
Intervention	Psychotherapeutic treatment programs for patients with personality pathology that will be distinguished from one another according to the following dosages: 1. Short (maximum of six months) outpatient 2. Short day hospital 3. Short inpatient 4. Long (at least six months) outpatient 5. Long day hospital 6. Long inpatient
Intervention type	Other
Primary outcome measure(s)	1. Structural improvement of personality pathology (assessed with the Outcome Questionnaire [OQ45], and the Severity Indices of Personality Problems [SIPP]) 2. Quality Adjusted Life Years (QALYs)
Key secondary outcome measure(s)	1. Symptomatic improvement (assessed with the Symptoms CheckList [SCL-90]) 2. Functional improvement (assessed with, amongst others, questions regarding work situation and care consumption) 3. Quality of life
Completion date	31/12/2008

Eligibility

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Target sample size at registration	821
Key inclusion criteria	1. At least one Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) axis-II diagnosis 2. An indication for psychotherapeutic treatment aiming at structural improvement of the personality pathology (besides symptomatic and/or functional improvement)
Key exclusion criteria	1. Insufficient command of Dutch language 2. Severe cognitive impairments 3. Mental retardation 4. Axis-I schizophrenia
Date of first enrolment	01/09/2003
Date of final enrolment	31/12/2008

Locations

Countries of recruitment

Netherlands

Study participating centre

Viersprong Institute for Studies on Personality Disorders (VISPD)

Halsteren
4660 AA
Netherlands

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes